Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Hollywood trade TheWrap is adding a subscription business by buying a subscription business

Sharon Waxman’s free site has bought Jocelyn Johnson’s VideoInk.

TheWrap CEO Sharon Waxman
TheWrap CEO Sharon Waxman
TheWrap CEO Sharon Waxman
Emma McIntyre / Getty
Peter Kafka
Peter Kafka covered media and technology, and their intersection, at Vox. Many of his stories can be found in his Kafka on Media newsletter, and he also hosts the Recode Media podcast.

Add another name to the paywall list: TheWrap, journalist Sharon Waxman’s nine-year-old Hollywood publication, is building a subscription product by buying a subscription site.

TheWrap has acquired VideoInk, a niche pub covering the ins and outs of digital media, and the digital video business in particular. VideoInk, which currently sells subscriptions for $30 per month, will keep operating under its current brand for now, but Waxman plans on eventually morphing it into a new brand, which she’ll call Wrap Pro.

Jocelyn Johnson, who founded VideoInk five years ago and has turned it into a site that often generates industry scoops, will go to work for Waxman, along with writer Matt Lopez. Waxman won’t disclose the sale price, but says she paid for the purchase with stock.

Waxman says she’ll keep her main site free but will use Wrap Pro to offer exclusive content to readers who care about the entertainment industry, along with other goodies like free access to or discounted tickets to gatherings she is hosting as part of a growing events business.

Waxman’s logic for adding a subscription business to her free site, which she says attracts 10 million visitors a month, is a now-common refrain: She worries that the digital advertising business, now dominated by Google and Facebook, doesn’t work for sites her size, which has bulked up from its trade roots by generating lots of general-interest entertainment content.

The flip side of that argument: Now that it’s increasingly common for digital publications to sell subscriptions for their stuff, it will get harder to sell subscriptions for their stuff. Waxman’s commonsense answer: “It’s our job to make what we’re offering really worthwhile, really valuable, and really produce a benefit to our members.”

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh